secwatch.observer — SEC 8-K summary
======================================

Issuer:     Polaryx Therapeutics, Inc. (PLYX)
CIK:        0002075320
Form:       8-K
Filed at:   2026-05-28T20:31:45+00:00
Accession:  0001213900-26-062155
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Polaryx closes $10M PIPE at ~$4.00/share to fund Phase 2 SOTERIA basket trial
-----------------------------------------------------------------------------

- Private placement of 2,502,696 common shares at avg $4.00/share for $10M gross proceeds to ~35 investors.
- Largest stockholder MStone Partners Healthcare purchased 88,453 shares ($360k) in the offering.
- Net proceeds will fund initiation of Phase 2 SOTERIA trial (CLN2, CLN3, Krabbe, Sandhoff) and extend cash runway through Q2 2027.
- No resale registration statement will be filed; shares issued under Section 4(a)(2) and Regulation S exemption.
- FDA Fast Track Designation already in place for all four planned LSD indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/0001213900-26-062155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-062155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer